Project Details
Description
A Phase 2 Randomized, Dose-blind, Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients with Autoimmune Hemolytic Anemia and Immune Thrombocytopenia
| Status | Finished |
|---|---|
| Effective start/end date | 8/20/19 → 9/1/20 |
Funding
- KEZAR LIFE SCIENCES, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.